Reading DGX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DGX free→Reading DGX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DGX free→QuarterlyIQ Insights · DGX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”). The Company will pay interest on the Notes on June 30 and December 30 of each year, beginning on December 30, 2026. The Notes will mature on June 30, 2036. The Notes will be the senior unsecured obligations of the Company and will rank equally with the Company’s other existing and future senior u…
Other Events On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay includes its $500 million…
Results of Operations and Financial Condition On April 21, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On March 9, 2026, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director. The Board appointed Mr. Wentworth to serve on the Board’s Compen…
Results of Operations and Financial Condition On February 10, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Other Events On February 10, 2026, the Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $1 billion of the Company's common stock as part of the Company's common stock repurchase program and increased the quarterly dividend from $0.80 to $0.86 per share. The 7.5% increase in the quarterly dividend is effective with the dividend payable on April 20, 2026 to shareholders of record of the Company’s common stock on A…
Results of Operations and Financial Condition To the extent applicable, the information furnished under
Results of Operations and Financial Condition On October 21, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Results of Operations and Financial Condition On July 22, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Results of Operations and Financial Condition On April 22, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Other Events On January 30, 2025, the Company announced that its Board of Directors had authorized a 6.7% increase in its quarterly dividend from $0.75 to $0.80 per share, or $3.20 per share annually, effective with the dividend payable on April 21, 2025 to shareholders of record of Quest Diagnostics Incorporated common stock on April 7, 2025. The Company has raised its dividend annually since 2011. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by r…
Results of Operations and Financial Condition On January 30, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Results of Operations and Financial Condition On October 22, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Other Events On August 26, 2024, Quest Diagnostics Incorporated (the “Company”) announced that it has closed its previously announced acquisition of LifeLabs Inc. (“LifeLabs”), pursuant to the terms of an equity purchase agreement that the Company and its wholly owned subsidiary entered into with Borealis Infrastructure Corporation, BPC Health Trust, LifeLabs and BPC Lab Finance LP, an Ontario limited partnership, on July 2, 2024. LifeLabs provides laboratory diagnostic information and digita…
Entry into a Material Definitive Agreement On August 19, 2024, Quest Diagnostics Incorporated (the “Company”) issued $400,000,000 aggregate principal amount of 4.600% senior notes due 2027 (the “2027 Notes”), $600,000,000 aggregate principal amount of 4.625% senior notes due 2029 (the “2029 Notes”) and $850,000,000 aggregate principal amount of 5.000% senior notes due 2034 (the “2034 Notes,” and together with the 2027 Notes and the 2029 Notes, the “Notes”). The Company will pay interest on th…
Results of Operations and Financial Condition On July 23, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Entry into a Material Definitive Agreement On July 2, 2024, Quest Diagnostics Incorporated (the “Company”) and 1000923563 Ontario Inc., a subsidiary of the Company (the “Buyer”), entered into an Equity Purchase Agreement (the “Agreement”) with Borealis Infrastructure Corporation, a corporation incorporated under the federal laws of Canada (“Borealis”), BPC Health Trust, a trust organized under the laws of the Province of Ontario (together with Borealis, the “Sellers”), LifeLabs Inc., a corpor…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On May 16, 2024, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board’s Governance Committee, elected Robert B. Carter to the Board. Mr. Carter is the Executive Vice President, Chief Information Officer of FedEx Corporation and Co-President and Co-CEO of FedEx…
Results of Operations and Financial Condition On April 23, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Other Events On February 1, 2024, the Company announced that its Board of Directors had authorized a 5.6% increase in its quarterly dividend from $0.71 to $0.75 per share, or $3.00 per share annually, effective with the dividend payable on April 22, 2024 to shareholders of record of Quest Diagnostics Incorporated common stock on April 8, 2024. The Company has raised its dividend annually since 2011. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by r…
Results of Operations and Financial Condition On February 1, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Entry into a Material Definitive Agreement On November 1, 2023, Quest Diagnostics Incorporated (the “Company”) issued $750,000,000 aggregate principal amount of 6.400% senior notes due 2033 (the “Notes”). The Company will pay interest on the Notes on May 30 and November 30 of each year, beginning on May 30, 2024. The Notes will mature on November 30, 2033. The Notes will be the senior unsecured obligations of the Company and will rank equally with the Company’s other existing and future senio…
Results of Operations and Financial Condition On October 24, 2023, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On September 28, 2023, Gail R. Wilensky, Ph.D. informed Quest Diagnostics Incorporated (the “Company”) of her decision to not seek re-election to the Company’s Board of Directors (the “Board”) at the Company’s Annual Meeting of Stockholders expected to be held May 2024 (the “2024 Annual Stockholders Meeting”), and to retire from the Board effect…
Results of Operations and Financial Condition On July 26, 2023, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.